|11 March 1999, Volume 18, Number 10, Pages 1867-1879|
|Table of contents Previous Article Next [PDF]
|Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells|
|Rosemarie Schmandt, Stanley K Liu and C Jane McGladea,b,c|
Ontario Cancer Institute, University of Toronto, 620 University Avenue, Suite 706, Toronto, Ontario, Canada M5G 2C1
aAuthor for correspondence
bCurrent address: Department of Medical Biophysics, University of Toronto, 620 University Avenue, Suite 706, Toronto, Ontario, Canada M5G 2C1
cCurrent address: The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
Shc adaptor proteins play a role in linking activated cell surface receptors to the Ras signaling pathway in response to receptor mediated tyrosine kinase activation. While the function of Shc in the activation of the Ras pathway via binding to Grb2 has been well characterized, it is becoming increasingly apparent that Shc participates in additional signaling pathways through interactions with other cytoplasmic proteins. Using the yeast two-hybrid system, we have identified a unique Shc binding protein designated PAL (Protein expressed in Activated Lymphocytes) with no similarity to other known proteins. mPAL binds specifically to the Shc SH2 domain and unlike previously described Shc SH2 domain-protein interactions, the association of mPAL and Shc is phosphotyrosine-independent. Both mPAL RNA and protein expression are restricted to tissues containing actively dividing cells and proliferating cells in culture. mPAL expression is induced upon growth factor stimulation and is down-regulated upon growth inhibition. This pattern, and timing of mPAL expression and its association with the Shc adaptor molecule suggests a role for this protein in signaling pathways governing cell cycle progression.
SHC; SH2 domain; phosphotyrosine-independent; cell proliferation
The ubiquitously expressed Shc adaptor proteins play a role in coupling growth factor receptor activation to intracellular signaling pathways. The mammalian Shc gene encodes three overlapping proteins with molecular weights of 46 kDa, 52 kDa and 66 kDa (Pelicci et al., 1992; Bonfini et al., 1996; Migliaccio et al., 1997). All three protein products share a carboxy terminal Src Homology 2 (SH2) domain, a central glycine/proline rich domain with homology to alpha1 collagen (CH1), and an amino terminal phosphotyrosine binding (PTB) domain. The p52 and p46 isoforms differ only by 46 amino acids at the extreme amino terminus of p52 and are generated by the use of alternative translation initiation sites (Pelicci et al., 1992). The p66 isoform is produced via alternative splicing of the Shc gene and contains an amino terminal extension which encodes a second collagen homology region (CH2) in addition to the common PTB, CH1, and SH2 domains. Interestingly, it has been demonstrated that the expression of p66 is more restricted and some of its biological properties distinct from those of p52 and p46 Shc (Bonfini et al., 1996; Migliaccio et al., 1997).
Shc proteins are tyrosine-phosphorylated following activation of receptor tyrosine kinases (van der Geer et al., 1994), including the epidermal growth factor receptor (EGFR) (Pelicci et al., 1992), platelet-derived growth factor receptor (PDGFR) (Yokote et al., 1994), nerve growth factor receptor (TrkA) (Obermeier et al., 1994), insulin receptor (Pronk et al., 1993) and erbB-2 (Segatto et al., 1993) as well as receptors that lack intrinsic tyrosine kinase activity such as the T-cell receptor (TCR) (Ravichandran et al., 1993), B-cell receptor (Saxton et al., 1994), receptors for the interleukins (Burns et al., 1993; Cutler et al., 1993; Ravichandran and Burakoff, 1994) and the erythropoietin receptor (Damen et al., 1993). Additionally, tyrosine phosphorylation of Shc has been detected after activation of G-protein coupled receptors (Cazubon et al., 1994; Ptaznik et al., 1995; Touhara et al., 1995; van Biesen et al., 1995; Chen et al., 1996), ligation of integrins (Maniero et al., 1995; Wary et al., 1996) and in cells expressing activated Src, Fps, Sea or Lck (McGlade et al., 1992a; Crowe et al., 1994; Baldari et al., 1995; Pelicci et al., 1995a), implicating Shc as an important substrate of cytoplasmic tyrosine kinases.
Shc is able to directly bind to tyrosine-phosphorylated proteins including activated receptor tyrosine kinases by virtue of its PTB or SH2 domains (Pawson, 1995; Bonfini et al., 1996). The PTB domain of Shc recognizes tyrosine-phosphorylated peptides in which residues amino terminal to the phosphorylated tyrosine determine binding specificity (Songyang et al., 1995; van der Geer et al., 1995). The Shc PTB domain has been shown to bind directly to N-P-X-pY sequence motifs in the cytoplasmic domains of the EGFR (Blaikie et al., 1994), TrkA (Dikic et al., 1995), RET (Lorenzo et al., 1997) and the IL-2R chain (Ravichandran et al., 1996). The Shc SH2 domain preferentially binds to tyrosine phosphorylated peptides in the sequence context pY-E/I-X-I/L/M (where X represents any amino acid) (Songyang et al., 1994) and has been proposed to mediate the binding of Shc to the PDGFR (Yokote et al., 1994), EGFR (Pelicci et al., 1992), RET (Lorenzo et al., 1997), and the CD3 zeta chain of the T-cell receptor (Ravichandran et al., 1993). While interactions between the Shc SH2 domain and several membrane receptors have been demonstrated, the physiologic importance of these interactions is less clear, since the PTB domain appears to be predominant in mediating the interaction of SHC with activated growth factor receptors.
Phosphorylated Shc proteins also associate with the Grb2 adaptor protein by binding of the Grb2 SH2 domain to the phosphorylated tyrosine residues within the CH1 domain of Shc (Rozakis-Adcock et al., 1992; Salcini et al., 1994). Grb2 is stably associated with the Ras guanine nucleotide exchange factor, SOS (Batzer et al., 1993; Buday and Downward, 1993; Chardin et al., 1993; Egan et al., 1993; Rozakis-Adcock et al., 1993) and membrane localization of the Grb2-SOS complex results in activation of Ras (Aronheim et al., 1994). Therefore it has been proposed that Shc is involved in coupling cell surface receptors to Ras activation. Several studies on the effects of Shc overexpression provide support for this hypothesis. First, coexpression of a dominant-negative mutant of Ras blocks neurite outgrowth in PC12 cells induced by Shc overexpression (Rozakis-Adcock et al., 1992). Second, overexpression of Shc in NIH3T3 fibroblasts results in transformation (Pelicci et al., 1992) and this can be abrogated by mutation of one of the presumed Grb2 binding sites (Salcini et al., 1994). As well, overexpression of Shc enhances EGF-induced activation of MAP kinases (Migliacciao et al., 1997) and cell motility and growth in response to hepatocyte growth factor (Pelicci et al., 1995b).
The modular structure of Shc proteins permits their interaction with multiple signaling molecules, suggesting that Shc could function to couple activated receptors to pathways other than Ras. Two additional sites of Shc tyrosine phosphorylation have recently been mapped to tyrosine residues 239 and 240 (Y239/240) (Gotoh et al., 1996; Harmer and DeFranco, 1997; van der Geer et al., 1996). Tyrosine 239 is present within a Grb2 SH2 domain-binding motif, and has been demonstrated to mediate association with Grb2 in vivo (Gotoh et al., 1997; Harmer and DeFranco, 1997). The Y239/240 phosphorylation sites may also couple Shc to additional downstream SH2 domain-containing proteins, since phosphopeptides corresponding to Y239/240 have been demonstrated to bind to several unidentified proteins and to the newly identified adaptor protein Gads (van der Geer et al., 1996; Liu and McGlade, 1998). A novel role for Shc has been suggested in which phosphorylation of Y239/Y240 leads to c-myc induction and suppression of apoptosis in Ba/F3 cells, in a Ras-independent manner (Gotoh et al., 1996). The Shc PTB domain binds directly to the cytoplasmic enzyme SHIP, an SH2 domain-containing inositol 5-phosphatase, in response to growth factor and cytokine stimulation in hematopoetic cells (Damen et al., 1996; Kavanaugh et al., 1996; Lioubin et al., 1996). Furthermore, proline-rich sequences in the Shc CH1 domain are proposed to mediate the interaction between Shc and the SH3 domain of eps8, a tyrosine-phosphorylated protein involved in EGF receptor-mediated signaling (Matoskova et al., 1995; Bonfini et al., 1996). Therefore, it is likely that Shc participates in diverse signal transduction pathways by interacting with multiple cytoplasmic signaling molecules.
We have used the two-hybrid system in yeast to screen cDNA libraries for proteins which interact with p52 Shc. Previously, using this technique, we mapped the interaction between the PTB domain of Shc and a specific sequence (NPLH) in the carboxy-terminal region of the tyrosine phosphatase PTP-PEST. These studies were the first to demonstrate tyrosine phosphorylation-independent binding by Shc PTB domain to target sequences (Charest et al., 1996). In this study we describe the cloning and characterization of mPAL, a protein that interacts with Shc and whose expression is restricted to proliferating cells. The association of mPAL with Shc occurs via a novel phosphotyrosine-independent interaction with the Shc SH2 domain.
Cloning of Shc binding proteins using the yeast-two-hybrid system
In order to identify binding partners for p52 Shc we used the yeast two-hybrid system. One of the clones isolated when full-length p52 Shc was used as a bait encodes a novel protein sequence designated mPAL which was isolated multiple times from both T-cell (three clones) and 11.5 day mouse embryo libraries (eight clones). This molecule interacts specifically with Shc and not with other non-specific GAL4 fusions tested. Furthermore, mPAL interacted with the isolated SH2 domain of p52 Shc but not the CH1 or PTB domain (data not shown). One of the cDNAs isolated from the yeast two-hybrid screen, encoding nucleotides 42 - 2130, was used to screen a mouse spleen library (Stratagene). No additional 5' or 3' cDNA sequences were identified by this approach so 5' and 3' RACE was used to amplify mPAL cDNA from mouse embryo cDNA.
The combined cDNA clone encompasses 2246 bp (Figure 1a). The 2007 bp open reading frame of mPAL includes nucleotides 12 - 2018. The first in-frame methionine (at nucleotide 12) is a good match for the Kozak consensus sequence (Kozak, 1992) and is used here to designate the initiation codon. Thus the cDNA of mPAL encodes a protein of 668 amino acids with a predicted molecular weight of 75 917 Daltons. A second in-frame methionine occurs 16 amino acids carboxy-terminal to the first, and also appears to be a good match for the Kozak consensus sequence. If this secondary site was used as an initiation codon, a protein of 653 amino acids would be produced with a predicted molecular weight of 74 407 Daltons.
The predicted mPAL protein sequence contains no known protein domains. mPAL contains 23 tyrosine residues, several of which are embedded in good consensus binding motifs for SH2 domains. In addition, two highly acidic regions are encoded in the mPAL sequence. Comparison of both the nucleotide and protein sequences of mPAL with the GenBank databases revealed no significant homology between mPAL and any previously identified proteins. We have isolated a cDNA encoding the human homolog of mPAL which shares 78.2% amino acid identity, with mPAL suggesting that the PAL protein is well conserved between species. In addition, several short murine and human ESTs with approximately 50% amino acid sequence identity to regions of mPAL were identified suggesting that additional mPAL related genes may exist. Interestingly, a partial genomic sequence has also been identified in Drosophila which encodes a protein that shares 26.8% identity with amino acids 115 - 277 in mPAL, and may represent a mPAL related gene in Drosophila (Accession number, AC004364).
Generation of anti-PAL anti-serum and identification of the PAL protein in cell lines
In order to study mPAL protein distribution, polyclonal antibodies were raised in rabbits against a 15 amino acid peptide corresponding to amino acids 17 - 31 of mPAL. Anti-mPAL antibodies specifically recognized in vitro transcribed and translated mPAL (mPAL met2) both by immunoprecipitation and Western blot analysis (Figure 2). Anti-mPAL antibodies were also used for immunoprecipitations from the murine embryonic cell line, P19. Western blot analysis detected an immunoprecipitating protein of 75 kDa which migrated with approximately the same mobility as in vitro transcribed and translated mPAL. Immunoprecipitation of in vitro transcribed and translated mPAL as well as mPAL immunoprecipitated from undifferentiated P19 cells was blocked by preincubation of the antibody with immunizing peptide, further demonstrating the specificity of this antiserum (Figure 2). The anti-mPAL antibodies are species specific because they do not immunoprecipitate PAL from cell lines derived from species other than mouse. In fact, cloning of human PAL has confirmed that the amino terminal sequence against which our anti-mPAL antibodies were raised is not well conserved in the human protein sequence (RS and JM, unpublished).
The 75 kDa band detected by anti-mPAL antibodies in immunoprecipitates from undifferentiated P19 cells was resolved into two closely migrating bands by SDS - PAGE. In vitro transcription and translation of mPAL revealed that this doublet is likely generated by the use of two initiation codons at positions 12 and 56 of the mPAL cDNA (data not shown). This suggests that two isoforms of mPAL are produced in vivo, the shorter of which lacks the amino terminal 15 amino acids.
In vivo association between and mPAL and Shc
To determine if an in vivo association could be detected between mPAL and Shc, a co-immunoprecipitation assay was performed using the human embryonic kidney cell line (293T) co-transfected with pECE-Shc and pcDNA3.1-mPAL expression vectors. The transfected cells were lysed, immunoprecipitated with an irrelevant antibody (rabbit anti-mouse IgG), anti-Shc or anti-mPAL antibodies, followed by immunoblotting with anti-Shc and anti-mPAL antibodies (Figure 3a). The characteristic doublet indicative of p52 and p46 Shc was present in the mPAL immunoprecipitate, and likewise, a 75 kDa protein corresponding to mPAL was detected in the Shc immunoprecipitate, indicating that Shc and mPAL associate in vivo. The presence of mPAL immunizing peptide prevented the immunoprecipitation of mPAL and consequently, Shc was no longer observed to co-immunoprecipitate. The p66 isoform of Shc was also observed to co-immunoprecipitate with mPAL (data not shown), indicating that the Shc-mPAL interaction is not limited to the p46 and p52 Shc isoforms. Neither Shc nor mPAL were non-specifically immunoprecipitated by the irrelevant antibody.
The SH2 domain of Shc specifically associates with mPAL
To determine which domain of Shc associated with mPAL in vitro, precipitation experiments were performed in which immobilized GST and GST-fusion proteins corresponding to the PTB, CH1 or SH2 domain of Shc were incubated with lysate from pcDNA3.1-mPAL-transfected 293T cells, and then subjected to immunoblotting with anti-mPAL antibody (Figure 4a). Only the GST-SH2 domain of Shc (GST-Shc SH2) was able to precipitate mPAL, indicating that this domain is involved in mediating the association of Shc with mPAL. Similarly, a yeast two-hybrid binding study utilizing the Shc PTB, CH1 and SH2 domains in isolation as bait, confirmed that only the Shc SH2 domain is necessary for interaction with mPAL (data not shown).
To examine the specificity of the mPAL-Shc SH2 interaction, a series of GST-SH2 fusion proteins generated from several signal transduction molecules were tested for their ability to precipitate mPAL (Figure 4b). None of the other GST-SH2 domains tested were found to bind to mPAL, indicating that association of the Shc SH2 domain with mPAL was specific.
The interaction of mPAL with the Shc SH2 domain is not dependent on phosphorylation of mPAL
In the previous experiments, mPAL precipitated by the Shc SH2 domain was not detected by immunoblotting with anti-pY antibodies (data not shown), suggesting that tyrosine-phosphorylation of mPAL is not critical for Shc SH2 domain-binding. Additionally, the interaction observed between mPAL and Shc in the yeast-two hybrid system strongly suggests that this interaction is independent of tyrosine-phosphorylation. Furthermore, by virtue of its production in E. Coli, recombinant GST-mPAL is not tyrosine-phosphorylated and yet is able to precipitate Shc from NIH3T3 lysate (Figure 5a), supporting the view that tyrosine-phosphorylation of mPAL is not important in the mPAL-Shc SH2 domain interaction.
Serine/theronine-phosphorylation-dependent SH2 binding has been reported (Cleghon and Morrison, 1994; Malek and Desiderio, 1994; Pendergast et al., 1991) and thus it was of interest to determine if the mPAL-Shc SH2 interaction was phosphorylation-dependent. However, no phosphoproteins are immunoprecipitated with anti-mPAL antibodies from in vivo 32P-orthophosphate labeled undifferentiated P19 cells or proliferating NIH3T3 cells, indicating that mPAL is not a phosphoprotein (data not shown). However, free phosphotyrosine competed for binding of mPAL to the Shc SH2 domain, whereas free phosphoserine or phosphothreonine did not (Figure 5b), implying that excess free phosphotyrosine, which is able to occupy the phosphotyrosine-binding pocket of the Shc SH2 domain, prevented interaction with mPAL. In addition, an arginine-to-alanine mutation in the conserved FLVRES motif (R397A) in the B region of the Shc SH2 domain, which disrupts its interaction with phosphorylated EGF receptors also abrogated binding of GST-Shc SH2 to mPAL in vitro (Figure 5c). Similarly, the R397A mutation in full length Shc abolished the co-immunoprecipitation of mPAL and Shc in vivo (Figure 5d). This suggests that the mPAL-Shc SH2 interaction requires structural elements similar to those involved in SH2 phosphotyrosine-peptide interactions.
Expression of mPAL in murine tissues
A single mPAL RNA transcript of less than 2.4 kb in size was identified by Northern blot analysis of RNA isolated from a variety of murine tissues as well as from murine embryos at various stages of development (Figure 6). This size is in agreement with the cDNA size of 2.2 kb. mPAL RNA was strongly expressed in RNA isolated from testis, and was present at a much lower level in spleen, lung and heart, but was absent from brain, liver, skeletal muscle. mPAL RNA was observed at all stages of embryonic development (data not shown). This pattern of expression suggests that mPAL expression is restricted to tissues containing a proliferating cell population, but is absent from quiescent tissues. The low levels of mPAL RNA detected in murine lung and heart may result from tissue contamination with activated lymphocytes which express high levels of mPAL (Figure 9).
In agreement with data obtained by Northern blot analysis, mPAL protein was expressed in mouse spleen, testis and thymus all of which contain proliferating cells, but was absent from normal quiescent tissues (data not shown). In addition, mPAL protein levels are elevated in all murine cell lines tested to date, provided that the cells are actively proliferating. Furthermore, when murine PAL cDNA was used to probe a human tumour cell line Northern blot, elevated levels of human PAL RNA were detected in all lines (RS and JM, unpublished data). Overall, the pattern of expression of mPAL RNA and protein support a role for mPAL in signaling pathways governing cellular proliferation.
Induction of mPAL by addition of exogenous growth factors
To determine whether mPAL expression could be induced by exogenous growth factors and to study mPAL levels during the cell cycle, serum starved NIH3T3 cells were treated with fresh media containing 20% fetal bovine serum and total RNA was extracted at various time points. Quiescent, serum starved NIH3T3 cells do not express detectable levels of mPAL RNA (Figure 7). mPAL RNA levels remained undetectable for 8 h following addition of serum, however expression increased detectably by 12 - 32 h when RNA levels were high, while Shc RNA levels remain constant throughout the cell cycle (Figure 7a). Detectable mPAL protein expression appeared to lag behind RNA levels, as mPAL protein is only detectable at the 16 h time point (Figure 7b). mPAL protein levels increase from 16 - 20 h and remain constant thereafter. By comparison, Shc protein levels are unchanged in both quiescent and cycling cells. The moderate increase in Shc protein levels observed following 20 h is most likely related to an increase in cell number or protein content at these late time points. Cell cycle analysis demonstrated a well synchronized passage of these cells through the cell cycle following addition of fetal calf serum (Figure 7c). Cells remained primarily in G0/G1 through 8 h of stimulation, and began to enter S phase by 12 h. The majority of cells had passed through G2/M by 20 - 24 h and had re-entered G0/G1. Despite re-entry into G0/G1, levels of mPAL RNA and protein remained constant in actively cycling cells. Taken together, these data indicate that mPAL expression is low or absent in cells in G0/G1, but is elevated in cells committed to cell cycle progression, or actively cycling cells.
Expression of mPAL is down-regulated in cell lines by contact inhibition and terminal differentiation
Since mPAL mRNA and protein levels appeared to correlate with cell proliferation in tissues, levels of RNA were analysed in proliferating versus contact inhibited NIH3T3 cells in culture. NIH3T3 cells were plated at approximately 50% confluence in DMEM supplemented with 10% fetal bovine serum, and allowed to proliferate over several days. Levels of mPAL RNA were measured by Northern blot analysis and evaluated relative to cell confluence (Figure 8a). Actively growing, subconfluent NIH3T3 cells expressed relatively high levels of mPAL RNA, however, within 24 h after confluence was reached, levels of mPAL RNA decreased to undetectable levels. In contrast, Shc RNA levels remained constant throughout the time course, irrespective of cell density.
The embryonic carcinoma cell line, P19, can be induced to differentiate to a neural phenotype by incubation with retinoic acid and to a muscle phenotype with DMSO (McBurney, 1993). Following 6 - 7 days of treatment with retinoic acid, as many as 85% of P19 cells have been demonstrated to express neuronal markers and become post-mitotic (McBurney et al., 1988; McBurney, 1993). DMSO-treated P19 cells differentiate towards mesodermal and endodermal lineages. Approximately 25% cardiac muscle cells are observed following 6 - 7 days of DMSO treatment (Rudnicki et al., 1990; McBurney, 1993), while the remainder of cells in culture continue to grow and differentiate into skeletal muscle as well as other less well defined cell types (McBurney, 1993). Levels of mPAL protein were measured by immunoprecipitation and Western blot analysis in P19 cells induced to differentiate in the presence of retinoic acid or DMSO (Figure 8b). While the parental, rapidly proliferating cell line expressed mPAL protein, DMSO-differentiated P19 cells expressed significantly lower levels of mPAL. Furthermore, in P19 cells treated for 7 days in the presence of retinoic acid, mPAL is virtually undetectable. Levels of -tubulin remain constant throughout differentiation. These data further support the hypothesis that mPAL expression is restricted to proliferating cells and is down-regulated upon growth inhibition.
T-cell activation results in mPAL expression and the formation of a mPAL-Shc complex
The restricted expression pattern of mPAL suggested that the association of Shc and mPAL in vivo might be limited to specific cell types or to cells which have been induced to proliferate and therefore express high levels of mPAL protein. Since the proliferation rate of primary T-cells is readily regulated in vitro, the levels of mPAL expression and its association with Shc were investigated in resting versus activated T-cells. Primary mouse lymphocytes, activated by cross-linking CD3, expressed high levels of mPAL while unstimulated cells did not (Figure 9a). The timing of the expression of mPAL was coincident with T-cell activation and proliferation. Shc immunoblots of anti-mPAL immunoprecipitates revealed the coprecipitation of Shc with mPAL following T-cell activation and concurrent with mPAL expression. Furthermore, constitutively activated primary T-cells isolated from a CTLA4 deficient mouse (Waterhouse et al., 1995; Marengere et al., 1996) expressed mPAL protein while mPAL was undetectable in T-cells isolated from a wild type mouse (Figure 9b). Immunoprecipitation of mPAL and Shc, followed by immunoblotting with anti-mPAL and anti-Shc clearly demonstrated the coprecipitation of mPAL with Shc from the CTLA4 deficient T-cell lysates but not from unstimulated wild type cells. Likewise Shc was present only in anti-mPAL precipitates from CTLA4 deficient lymphocytes (Figure 9b).
This paper reports the cloning and characterization of a novel Shc SH2 binding protein which we have designated mPAL (murine Protein expressed in Activated Lymphocytes). The mPAL protein sequence contains no known protein domains and appears to be unrelated to previously identified proteins. The mPAL protein is conserved because we have also identified a human cDNA encoding a protein 78.2% identical to mPAL (RS and JM, unpublished data). In addition, a partial cDNA encoding a rat homolog of mPAL has been isolated from undifferentiated PC-12 cells which shares 92.5% identity with mPAL (Lee et al., 1995). The partial sequence of a Drosophila gene also has been reported in GenBank (accession number, AC004364) which encodes a protein 26.8% identical to mPAL and may represent a mPAL-related protein.
mPAL was isolated in a yeast-two-hybrid screen from murine T-cell and embryo libraries in which the p52 isoform of Shc was used as `bait'. In addition we have observed an in vivo interaction between Shc and mPAL in mammalian cells by co-immunoprecipitation. mPAL binds to Shc via its SH2 domain and this interaction is specific because SH2 domains from other proteins did not bind mPAL. Furthermore, the mechanism of SH2 binding is novel. Unlike other SH2 domain-phosphopeptide interactions, the mPAL-Shc SH2 domain interaction appears to be independent of tyrosine-phosphorylation. Similar phosphotyrosine-independent interactions with SH2 domains have been described between Lck and the ubiquitin binding protein p62 (Joung et al., 1996; Vadlamudi et al., 1996), between v-abl and Shc (Raffel et al., 1996) as well as between Grb10 and the Raf1 and MEK1 kinases (Nantel et al., 1998).
Structural elements involved in Shc SH2 domain-phosphotyrosine peptide interactions may mediate the mPAL-Shc SH2 domain interaction, since occupancy of the phosphotyrosine-binding pocket with free phosphotyrosine, or mutation of the conserved R397 residue involved in phosphotyrosine binding disrupts the mPAL-Shc SH2 domain interaction. Alternatively, mPAL could be binding a region near the Shc SH2 phosphotyrosine binding pocket and phosphotyrosine binding or the R397A mutation may alter the conformation of the SH2 domain, or local charge distribution on the domain surface and disrupt the mPAL binding site. Further characterization of the exact sequences of mPAL required for Shc-SH2 domain binding will be required to resolve the molecular basis of the mPAL and Shc interaction. It is possible that binding of mPAL to the Shc SH2 domain is mediated by the acidic regions in mPAL because phosphotyrosine-independent interactions between SH2 domains of other proteins such as Bcr-Abl, Lck and Blk and sequences rich in serine and glutamic acid have been previously reported (Pendergast et al., 1991; Malek and Desiderio, 1994; Joung et al., 1996). In some cases, serine phosphorylation has been shown to be important for SH2 domain binding (Pendergast et al., 1991; Malek and Desiderio, 1994). This does not appear to be the case for the mPAL-Shc interaction since the interaction cannot be competed for by free phosphoserine or phosphothreonine, and we have been unable to detect any phosphorylation of the mPAL protein.
The binding of the Shc SH2 domain to mPAL represents an alternative role for the Shc SH2 domain which had previously been reported to couple Shc to activated transmembrane receptors rather than downstream cytoplasmic signaling molecules. In fact, there is growing evidence that Shc binds to proteins distal to receptor tyrosine kinases via its SH2 domain. The isolated Shc SH2 domain has been demonstrated to function as a dominant-negative mutant and block signaling from the PDGF and EGF receptors (Gotoh et al., 1995; Ricketts et al., 1996; Roche et al., 1996). Furthermore, the Shc SH2 domain can effectively block EGF signaling in cells, even if introduced as much as 10 min following EGF stimulation (Ricketts et al., 1996). Consistent with these observations, expression the SH2 domain of the neural specific ShcC adaptor protein has been shown to block Erk1 and Erk2 activation by the EGF receptor and to inhibit EGF receptor mediated transformation of cells, however association of the isolated Shc SH2 domain and the activated receptor is undetectable (O'Bryan et al., 1998). These data have led both Ricketts et al. (1996) and O'Bryan et al. (1998) to hypothesize that the Shc SH2 domain serves an important function at a point distal to EGF receptor activation and that additional proteins are required for EGF receptor signaling. We have demonstrated by subcellular fractionation and by expression of Green Fluorescent Protein-labeled mPAL in mammalian cell lines that mPAL is primarily a cytoplasmic protein (data not shown) and may therefore represent a downstream target of the Shc SH2 domain following receptor activation.
mPAL mRNA and protein are elevated in tissues containing proliferating cells and in cell lines, but are absent in normal, quiescent tissues and growth-arrested cells. Factors which stimulate cell cycle progression and proliferation also stimulate mPAL expression, whereas factors which inhibit cellular proliferation including serum withdrawal, contact inhibition, and terminal differentiation, inhibit the expression of mPAL. Interestingly, a partial cDNA encoding mPAL was identified as a gene expressed in fertilized single cell mouse embryo (accession C87425). These data support a role for mPAL in cell growth and differentiation. mPAL may be involved in progression through the cell cycle rather than the immediate early response because mPAL mRNA is expressed during entry into S phase and passage through G2/M. Preliminary data from cyclohexamide treated cells also supports the hypothesis that mPAL is not an immediate early response gene (data not shown). Microinjection of the Shc SH2 domain or anti-Shc antibodies has been shown to inhibit both S phase entry and Fos induction in PDGF stimulated NIH3T3 cells (Roche et al., 1996). Since mPAL is a target of the Shc SH2 domain, it is possible that mPAL represents a component of the growth regulatory pathway blocked by Shc dominant-negative mutants.
Given that mPAL was isolated from a T-cell library and T-cells represent a normal cell lineage whose proliferative rate is readily regulated in culture, we also studied mPAL expression and its association with Shc in response to T-cell activation. While unstimulated T-cells lack mPAL protein, T-cells activated by cross-linking the T-cell receptor and constitutively activated T-cells isolated from CTLA4-/- mice express high levels of mPAL. Furthermore, Shc and mPAL complexes were found to co-immunoprecipitate from activated T-cells, albeit at low levels. The percentage of mPAL which can be detected in complex with Shc probably under-represents the actual amount Shc-mPAL in the cell. This may be due in part to the antibodies used to detect Shc, since they are directed against the SH2 domain and therefore may not efficiently precipitate Shc proteins in which the SH2 domain is complexed with another molecule. Since mPAL protein is detectable only in proliferating T-cells, the formation of a mPAL-Shc complex is regulated, at least in part, by mPAL expression levels.
The function of mPAL in cell cycle progression and the physiologic outcome of the mPAL-Shc interaction remains to be determined. The association of mPAL with the Shc SH2 domain could imply that mPAL is a component of a novel signaling pathway downstream of Shc. Alternatively, mPAL could regulate Shc function by modifying complex formation between the Shc SH2 domain and tyrosine phosphorylated targets. Taken together, the data presented here indicate that mPAL may function in signaling pathways governing cell cycle progression.
Materials and methods
Unless otherwise indicated, reagents were purchased from Sigma chemicals.
Full length human p52 Shc was fused to the DNA binding domain of GAL4 (GAL4-DB) by cloning into pAS-1. The yeast strain used (Y153) contained both HIS3 and lacZ reporter genes driven by promoters containing GAL4 binding sites, and was deleted for endogenous GAL4 (Bai and Elledge, 1996). Yeast transformed with pAS-1 GAL4-Shc were screened for expression of the GAL4-Shc fusion protein by Western blot analysis of yeast lysates using anti-Shc antibodies (data not shown). The GAL4 Shc expressing strain was assayed for transcriptional activation of HIS3 and lacZ, and was negative for auto-activation of GAL4 driven promoters. A plasmid cDNA-GAL4 transactivation domain (GAL4-TA) fusion library, derived from total T-cell cDNA (a generous gift from S Elledge) and, a mouse embryo GAL4-TA fusion library (Clontech) were used to transform yeast carrying the GAL4-Shc DB fusion constructs and interacting clones were selected on his- media supplemented with 20 mM aminotriazole. After 72 h nitrocellulose replicas were made and assayed for -galactosidase activity directly. Over 3´106 clones were screened from both libraries and 42 and 100 His and -gal positive clones were picked up from the T-cell and embryo libraries, respectively. The isolated cDNAs were checked for insert size and introduced into a second strain of yeast (Y187) and tested for -galactosidase activity alone, or when mated with yeast carrying either GAL-Shc or GAL4 fused to other unrelated proteins to eliminate false positives.
A mouse spleen library was screened with the mPAL cDNA isolated from the yeast-two-hybrid screen. cDNAs corresponding to nucleotides 42 - 2130 encoding mPAL amino acids 16 - 668, were subcloned into Bluescript SK- (Stratagene) and utilized for in vitro transcription and translation (mPAL met2).
The remaining 5' and 3' cDNA ends of mPAL were identified using 5' and 3' RACE of Marathon Ready cDNAs (Clontech) from murine embryo and spleen as per manufacturer's instructions. A full length construct encoding mPAL amino acids 1 - 668 was cloned by PCR from murine embryo Marathon Ready cDNA and cloned directly into pCR2.1 (Invitrogen). This construct was sequenced for accuracy and was used for in vitro transcription and translation (mPAL met1).
P19 and 293T cells were cultured in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (Sigma), 200 mM L-glutamine, 5´10-5 M -mercaptoethanol, 5 U/ml penicillin C and 5 g/ml streptomycin sulfate. NIH3T3 cells were cultured in 10% calf serum (Sigma), 200 mM L-glutamine, 5´10-5 M -mercaptoethanol, 5 U/ml penicillin C and 5 g/ml streptomycin sulfate.
In order to characterize the serum mediated induction of mPAL, NIH3T3 cells were grown to 70 - 80% confluence, washed twice in phosphate buffered saline (PBS) and then transferred to media containing 0.5% fetal bovine serum for 48 h to achieve quiescence. Serum starved cells were then transferred to media containing 20% fetal bovine serum. Samples were harvested for protein or RNA isolation at the times indicated. Cells isolated at each time point were stained with propidium iodide and subjected to cell cycle analysis by flow cytometry.
P19 cells were differentiated to a neural phenotype following incubation for 6 - 7 days in the presence of 5´10-7 M retinoic acid or a muscle phenotype by incubation with 0.75% DMSO for 5 days. Techniques used were as described by Jones-Villeneuve et al. (1982) and McBurney et al. (1982).
Primary murine T-cells were isolated from wild type and CTLA4 deficient mice (a kind gift of Luc Marengere). Wild type murine T-cells were activated by cross-linking the T-cell receptor on anti-CD3 coated tissue culture plates as described by Marengere et al. (1997).
Preparation of GST-fusion proteins
The Shc SH2 mutant (R397A) was engineered using PCR-based site-directed mutagenesis. The PCR product containing the R397A mutation was cloned using BamHI and EcoRI restriction sites into the pGEX-2T vector (Pharmacia). The PAL cDNA encoding amino acids 11 - 648 was cloned using XhoI restriction sites into the pGEX-4T3 vector (Pharmacia). Additional GST-fusion proteins; Shc PTB (Blaikie et al., 1994); Shc SH2 (Pelicci et al., 1992); Grb2 SH2 (Rozakis-Adcock et al., 1992); Vav SH2 (Margolis et al., 1992); GAP-N SH2, PLC-N SH2, PLC-C SH2 (Anderson et al., 1990); and p85-N SH2, p85-C SH2 (McGlade et al., 1992b) have been previously described. Nck SH2 contains amino acids 281 - 377 of human Nck (Lehman et al., 1990), and the GST Shc-CH1 consists of amino acids 212 - 376 of human Shc. GST-SH2 fusion proteins were prepared as follows: log-phase Escherichia coli (E. Coli) DH5- cells were grown in the presence of 100 g/ml amphicillin, and induced with 1 mM isopropythiogalactopyranoside (IPTG) for 3 h at 37°C. The cells were pelleted, lysed in 1 ml of ice-cold NP-40 lysis buffer (50 mM HEPES, pH 7.25, 150 mM NaCl, 2 mM EDTA, 100 M ZnCl2, 1% (v/v) Nonidet-P40, 100 M sodium pervanadate, 10% (v/v) glycerol, 10 g/ml aprotinin, 10 g/ml leupeptin and 1 mM Pefa-Bloc), sonicated on ice three times for 30 s, and the lysates clarified by centrifugation for 10 min at 11 000 r.p.m., 4°C. The lysates were incubated with glutathione-Sepharose beads (Pharmacia) for 30 min at 4°C, the beads washed several times with NP-40 lysis buffer, and resuspended in an equal volume of phosphate-buffered saline (PBS) containing 1 mM dithiothreitol (DTT). Each of the purified GST-fusion proteins was quantitated by SDS - PAGE followed by Coomassie staining and comparison with known BSA standards.
Human p52 Shc in pECE has been previously described (Pelicci et al., 1992). The mouse p66 Shc cDNA was subcloned into pcDNA1 (unpublished). Mouse p52 Shc with an activated SH2 domain was generated through PCR-based mutagenesis (R397 mutated to A). The PAL cDNA encoding amino acids 11 - 648 was cloned into pcDNA3.1 (Invitrogen). 293T cells in 10 cm culture dishes were transfected with 10 g of pECE-Shc and/or pcDNA3.1-mPAL expression vectors using Lipofectin (Gibco-BRL) according to manufacturer's instructions.
Anti-mPAL antibodies were raised in rabbits against the peptide sequence VPPRPDLAAEKEPAS, corresponding to amino acids 17 - 31 in the predicted protein sequence of mPAL. An carboxy-terminal cysteine was added to facilitate conjunction to keyhold limpet haemocyanin (KLH) and to couple the peptide to a Sulfolink column (Pierce) used for affinity purification of anti-mPAL antibodies. Crude anti-mPAL was used at a concentration of 1 : 500 for Western blot analysis and 20 l per immunoprecipitation. Affinity purified antibody was used at a final concentration of 1 g/ml for Western blotting and at 2 g per immunoprecipitation.
Affinity purified anti-Shc antibodies (Pelicci et al., 1992) were used at a 1 : 500 dilution for Western blot analysis and 2 g per immunoprecipitation. In some experiments, a monoclonal anti-Shc antibody (Transduction Laboratories) was used at a dilution of 1 : 250.
The anti-phosphotyrosine antibody RC20H (Transduction Laboratories) was used at a dilution of 1 : 2500 for Western blot analysis. The anti-phosphotyrosine antibody 4G10 (UBI) was used for Western blot analysis at a dilution of 1 : 1000, anti-EGFR antibody (Upstate Biotechnology) was used at a dilution of 1 : 500 for Western blot analysis, and anti--tubulin antibody (Amersham) was used at a concentration of 1 g/ml for Western blot analysis.
Immunoprecipitation and Western blot analysis
Each 10 cm plate of adherent cells was lysed in 1 ml of NP-40 lysis buffer for 15 min at 4°C. Tissue lysates were also homogenized in NP-40 lysis buffer using a polytron homogenizer (Kinematica AG). Lysates were transferred to a 1.5 ml microfuge tube and centrifuged at 10 000 g (maximum speed) for 10 min at 4°C. Typically, a volume of lysate containing 1 mg of total protein was incubated with 20 l crude anti-mPAL antiserum or 2 g affinity purified anti-mPAL antiserum and 100 l of 10% Protein A Sepharose (Sigma) and the volume increased to 1 ml with NP-40 lysis buffer. Samples were incubated at 4°C with gentle rotation for 1 h. Immune complexes were then washed three times in 1 ml NP-40 lysis buffer. Samples were boiled for 5 min in 40 l reducing SDS - Laemmli sample buffer prior to loading onto a 10% polyacrylamide gel and separation by SDS - PAGE. Proteins were electrophoretically transferred to Immobilon-P (PVDF) membrane (Millipore), and incubated in a blocking solution of 5% skim milk powder in TBST (20 mM Tris-HCl, pH 8.3, 150 mM NaCl, 0.05% Tween 20) for a minimum of 1 h prior to addition of antibody overnight at 4°C. Membranes were washed three times in TBST and incubated for 1 h at 4°C with a 1 : 3000 dilution of HRP-coupled protein A (Biorad). Following incubation with secondary antibodies, membranes were washed three times in TBST and developed using ECL (Amersham) as per manufacturer's instructions.
The cell lysates of transiently-transfected 293T cells were prepared as described above, and incubated with approximately 5 g of GST-fusion protein coupled to glutathione-Sepharose 4B beads for 2 h at 4°C. The beads were washed three times with NP-40 lysis buffer, resuspended in 25 L of SDS-sample buffer, the proteins resolved on a 10% SDS-polyacrylamide gel and transferred to Immobilon-P membrane. Immunoblotting and detection of immunoreactive bands was carried out as previously described.
Competition studies assessing the phosphotyrosine dependence of GST-Shc SH2 and mPAL association were carried out in the presence of 10, 50 and 100 mM O-phospho-L-threonine, O-phospho-L-serine, or O-phospho-L-tyrosine which were added to the cell lysates prior to incubation with immobilized GST-Shc SH2 fusion protein.
In vitro transcription and translation
T7 TNT-coupled Reticulocyte Lysate systems (Promega) was used to transcribe and translate cDNA constructs encoding full length mPAL amino acids 1 - 668 (met1) in PCR2.1 (Invitrogen) and amino acids 16 - 668 (met2) in Bluescript SK(-) (Stratagene) Bluescript SK, according to the manufacturer's instructions.
Northern blot analysis
Northern blots containing 2 g of poly(A)+ mRNA isolated from a variety of murine tissues and embryos were purchased from Clontech.
Where specified, total RNA was prepared from cultured cells using the TRIzol Reagent (Gibco/BRL) as per manu-facturer's instructions. RNA samples (10 g/lane) were separated on formaldehyde-agarose gels and transferred onto Genescreen nylon membrane (NEN-Dupont) as described by Sambrook et al., 1989.
Blots were probed with a 1522 bp AflIII/PstI fragment of the mPAL cDNA which was radiolabeled by random hex-amer priming (Pharmacia). Blots were initially prehybridized for 4 h at 42°C in a solution of 50% formamide, 4´SSPE, 1% SDS, 0.5% skim milk powder, 10% dextran sulfate and 10 mg/ml sheared salmon sperm DNA. 32P-Radiolabeled probe was then added at 106 c.p.m./ml and the blot further incubated for 16 h at 42°C. Blots were washed twice for 10 min at room temperature in 2´SSC, 0.1% SDS, then twice at 65°C in 0.1´SSC, 0.1% SDS and then exposed to film. The blots were also probed with radiolabeled -actin cDNA (Clontech) or Shc cDNA as an indicator of RNA loading.
The cDNA sequence of murine PAL has been submitted to GenBank (accession number: AF017152).
Rosemarie Schmandt and Stanley Liu contributed equally to the data presented in this paper. We thank Sascha Dho, Sara Jacob, Cheryl Wolting and Stacy Woods for technical assistance, David Grosshans for DNA sequencing, Andrew Hessel and Mike Bass for assistance with sequence analysis, Luc Marengere for the activated T-cell lysates, Denis Bouchard for assistance with FACS analysis, Marynette Rihaynek and the peptide synthesis group at AMGEN Boulder for antibody preparation and Tony Pawson, Ben Margolis, and Mike Moran for GST-fusion protein constructs. We also thank Dwayne Barber, Dan Dumont and Michelle French for critical reading of the manuscript. This work was supported by Amgen and operating funds from the Medical Research Council of Canada. RS is supported by an MRC postdoctoral fellowship.
Anderson D, Koch CA, Grey L, Ellis C, Moran MF and Pawson T. (1990). Science 250, 979-982. MEDLINE
Aronheim A, Engelberg D, Li N, Al-Alawi N, Schlessinger J and Karin M. (1994). Cell 78, 949-961. MEDLINE
Bai C and Elledge SJ. (1996). Methods Enzymol. 273, 331-347. MEDLINE
Baldari C, Pelicci G, Di Somma MM, Milia E, Giuli S, Pelicci PG and Telford JL. (1995). Oncogene 16, 1141-1147.
Batzer LN, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B and Schlessinger J. (1993). Nature 363, 85-88. MEDLINE
Blaikie P, Immanuel D, Wu D, Li N, Yajnik V and Margolis B. (1994). J. Biol. Chem. 269, 23031-32034.
Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L and Pelicci P. (1996). TIBS 21, 257-261. MEDLINE
Buday L and Downward J. (1993). Cell 73, 611-620. MEDLINE
Burns LA, Karnitz LM, Sutor SL and Abraham RT. (1993). J. Biol. Chem. 268, 17659-17661. MEDLINE
Cazaubon SM, Ramos-Morales F, Fischer S, Schweighoffer F, Strosberg AD and Couraud PO. (1994). J. Biol. Chem. 269, 24805-24809. MEDLINE
Chardin P, Camonis J, Gale WL, Van Aelst L, Schlessinger J, Wigler MH and Bar-sagi D. (1993). Science 260, 1338-1343. MEDLINE
Charest A, Wagner J, Jacob S, McGlade CJ and Tremblay ML. (1996). J. Biol. Chem. 272, 8424-8429.
Chen Y, Grall D, Salcini AE, Pelicci PG, Pouyssegur J and Van Obberghen-Schilling E. (1996). EMBO J. 15, 1037-1044. MEDLINE
Cleghon V and Morrison DK. (1994). J. Biol. Chem. 269, 17749-17755. MEDLINE
Crowe A, McGlade J, Pawson T and Hayman MJ. (1994). Oncogene 9, 537-544. MEDLINE
Cutler RL, Liu L, Damen JE and Krystal G. (1993). J. Biol. Chem. 268, 21463-21465. MEDLINE
Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW and Krystal G. (1996). Proc. Natl. Acad. Sci. USA 93, 1698-1693.
Damen JE, Liu L, Kutler RB and Krystal G. (1993). Blood 82, 2296-2303. MEDLINE
Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A, Schlessinger J and Margolis B. (1995). J. Biol. Chem. 270, 15125-15129. MEDLINE
Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM and Weinberg RA. (1993). Nature 363, 45-51. MEDLINE
Gotoh N, Muroya K, Hattori S, Nakamura S, Chida K and Shibuya M. (1995). Oncogene 11, 2525-2533. MEDLINE
Gotoh N, Toyoda M and Shibuya M. (1997). Mol. Cell. Biol. 17, 1824-1831. MEDLINE
Gotoh N, Tojo A and Shibuya M. (1996). EMBO J. 15, 6197-6204. MEDLINE
Harmer SL and DeFranco AL. (1997). Mol. Cell. Biol. 17, 4087-4095. MEDLINE
Jones-Villeneuve EMV, McBurney MW, Rogers KA and Kalnins VJ. (1982). J. Cell. Biol. 94, 253-262. MEDLINE
Joung I, Strominger JL and Shin J. (1996). Proc. Natl. Acad. Sci. USA 93, 5991-5995. MEDLINE
Kavanaugh WM, Pot DA, Chin SM, Deuter-Reinhard M, Jefferson AB, Norris FA, Masiarz FR, Cousens L, Majerus PW and Williams LT. (1996). Curr. Biol. 6, 438-445. MEDLINE
Kozak M. (1992). Annu. Rev. Cell. Biol. 8, 197-225. MEDLINE
Lee NH, Weinstock KG, Kirkless EF, Earle-Hughes JA, Fuldner RA, Marmaras S, Glodek A, Gocayne JD, Adams M, Kerlavage AR, Fraser CM and Venter JC. (1995). Proc. Natl. Acad. Sci. USA 92, 8303-8307. MEDLINE
Lehmann JM, Riethmuller G and Johnson JP. (1990). Nucl. Acids. Res. 18, 1048.
Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold R and Rohrschneider LR. (1996). Genes Dev. 10, 1084-1095. MEDLINE
Liu SK and McGlade CJ. (1998). Oncogene in press.
Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA and Smith DP. (1997). Oncogene 14, 763-771. MEDLINE
Malek SN and Desiderio S. (1994). J. Biol. Chem. 269, 33009-33020. MEDLINE
Maniero F, Pepe A, Wary KK, Spinardi L, Mohammadi M, Schlessinger J and Giancotti FG. (1995). EMBO J. 14, 4470-4481. MEDLINE
Marengere LEM, Mirtsos C, Kozieradzki I, Veillette A, Mak TW and Penninger JM. (1997). J. Immunol. 159, 70-76. MEDLINE
Marengere LEM, Waterhouse P, Duncan GS, Mittrucker H-W, Feng G-S and Mak TW. (1996). Science 272, 1170-1173. MEDLINE
Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A and Schlessinger J. (1992). Nature 356, 71-74. MEDLINE
Matoskova B, Wong TW, Salcini Ae, Pelicci PG and Difiore PP. (1995). Mol. Cell. Biol. 15, 3805-3812. MEDLINE
McBurney MW. (1993). Int. J. Dev. Biol. 37, 135-140. MEDLINE
McBurney MW, Jones-Villeneuve EMV, Edwards MKS and Anderson PJ. (1982). Nature 299, 165-167. MEDLINE
McBurney MW, Rheul KR, Ally AI, Nasipuri S, Bell JC and Craig J. (1988). J. Neurosci. 8, 1063-1073. MEDLINE
McGlade J, Cheng A, Pelicci G, Pelicci PG and Pawson T. (1992a)). Proc. Natl. Acad. Sci. USA 89, 8869-8873. MEDLINE
McGlade CJ, Ellis C, Reedijk M, Anderson D, Mbamalu G, Reith AD, Panayotou G, End P, Bernstein A, Kazlauskas A, Waterfield MD and Pawson T. (1992b). Mol. Cell. Biol. 12, 991-997. MEDLINE
Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai K, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L and Pelicci PG. (1997). EMBO J. 16, 706-716. Article MEDLINE
Nantel A, Mohammed-Ali K, Sherk J, Posner BI and Thomas DY. (1998). J. Biol. Chem. 273, 10473-10484.
O'Bryan JP, Lambert QT and Der Cj. (1998). J. Biol. Chem. 273, 20431-20437. Article MEDLINE
Obermeier A, Bradshaw BA, Seedorf K, Choidas A, Schlessinger J and Ullrich A. (1994). EMBO J. 13, 1585-1590. MEDLINE
Pawson T. (1995). Nature 373, 573-579. MEDLINE
Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, borrello MG, Segatto O, Di Fiore PP and Pelicci PG. (1995a). Oncogene 11, 899-907.
Pelicci G, Lanfrancone L, Grigani F, McGlade J, Cavallo F, forni G, Nicoletti I, Grignani F, Pawson T and Pelicci PG. (1992). Cell 70, 93-104. MEDLINE
Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pelicci PG and Comoglio PM. (1995b). Oncogene 10, 1631-1638. MEDLINE
Pendergast AM, Muller AJ, Havlik MH, Maru Y and Witte ON. (1991). Cell 66, 161-171. MEDLINE
Pronk GJ, McGlade J, Pelicci G, Pawson T and Bos LJ. (1993). J. Biol. Chem. 268, 5748-5753. MEDLINE
Ptaznik A, Traynor-Kaplan A and Bokoch GM. (1995). J. Biol. Chem. 270, 19969-19973. MEDLINE
Raffel GD, Parmar K and Rosenberg N. (1996). J. Biol. Chem. 271, 4640-4645. MEDLINE
Ravichandran KS, Lee K, Songyang Z, Cantley LC, Burn P and Burakoff SJ. (1993). Science 262, 902-905. MEDLINE
Ravichandran KS and Burakoff SJ. (1994). J. Biol. Chem. 269, 1599-1602. MEDLINE
Ravichandran KS, Igras V, Shoelson SE, Fesik SW and Burakoff SJ. (1996). Proc. Natl. Acad. Sci. USA 28, 5275-5280.
Ricketts WA, Rose DW, Shoelson S and Olefsky JM. (1996). J. Biol. Chem. 271, 26165-26169. MEDLINE
Roche S, McGlade J, Jones M, Gish GD, Pawson T and Courtneidge SA. (1996). EMBO J. 15, 4940-4946. MEDLINE
Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG and Pawson T. (1992). Nature 360, 689-692. MEDLINE
Rozakis-Adcock M, Fernley R, Wade J, Pawson T and Bowtell D. (1993). Nature 363, 83-85. MEDLINE
Rudnicki MA, Sawtell NM, Rheul KR, Berg R, Craig JC and McBurney MW. (1990). J. Cell Physiol. 142, 89-98. MEDLINE
Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T and Pelicci PG. (1994). Oncogene 9, 2827-2836. MEDLINE
Sambrook J, Fritsch EF and Maniatis T. (1989). Molecular Cloning: A Laboratory Manual. Second Edition. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.,
Saxton TM, van Oostveen I, Bowtell D, Aebersold R and Gold MR. (1994). J. Immunol. 153, 623-636. MEDLINE
Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T and Pelicci PG. (1993). Oncogene 9, 2105-2112.
Songyang Z, Margolis B, Chaudhuri M, Shoelson SE and Cantley LC. (1995). J. Biol. Chem. 270, 14863-14866. MEDLINE
Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Save H, Hanafusa H, Yi T, Ren R, Baltimore D, Ratnofsky S, Feldman RA and Cantley LC. (1994). Mol. Cell. Biol. 14, 2777-2785. MEDLINE
Touhara K, Hawes BE, van Biesen T and Lefkowitz RJ. (1995). Proc. Natl. Acad. Sci. USA 92, 9284-9287. MEDLINE
Vadlamudi RK, Young I, Strominger JL and Shin J. (1996). J. Biol. Chem. 271, 20235-20237. MEDLINE
van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM and Lefkowitz RJ. (1995). Nature 376, 781-784. MEDLINE
van der Geer P, Hunter T and Lindberg RA. (1994). Annu. Rev. Cell. Biol. 10, 251-337. MEDLINE
van der Geer P, Wiley S, Lai VK-M, Olivier JP, Gish GD, Stephens R, Kaplan D, Shoelson S and Pawson T. (1995). Curr. Biol. 5, 404-412. MEDLINE
van der Geer P, Wiley S, Gish GD and Pawson T. (1996). Curr. Biol. 6, 1435-1444. MEDLINE
Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE and Giancotti FG. (1996). Cell 87, 733-743. MEDLINE
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H and Mak TW. (1995). Science 270, 985-988. MEDLINE
Yokote K, Mori S, Hansen K, McGlade J, Pawson T. Heldin CH and Claesson-Welsch L. (1994). J. Biol. Chem. 269, 15337-15343. MEDLINE
Figure 1 Nucleotide and predicted amino acid sequence of mPAL. The cDNA and predicted amino acid sequence of mPAL is shown. The positions of two potential ATG initiation codons are circled. The peptide against which the anti-PAL antiserum was raised is underlined
Figure 2 Characterization of specific anti-mPAL antibodies. Undifferentiated P19 cell lysates and in vitro translation products (TNT mPAL met2) were immunoprecipitated with an anti-mPAL antibody in the presence or absence of 50 g immunizing peptide. Western blot analysis was completed with an anti-PAL antibody followed by HRP-Protein A
Figure 3 mPAL and Shc associate in vivo. The human embryonic kidney cell line (293T) was cotransfected with pECE-Shc and pcDNA3.1-mPAL (amino acids 16 - 668) expression vectors, lysed and immunoprecipitated with a non-specific antibody (RM IgG) or with anti-Shc and anti-mPAL antibodies in the presence or absence of 50 g immunizing peptide. The immunoprecipitates were washed three times, and the bound proteins resolved via SDS - PAGE. Following electrophoretic transfer to PVDF membrane, immunoblotting was performed with anti-Shc and anti-mPAL antibodies
Figure 4 mPAL binds specifically to the SH2 domain of Shc. (a) The PTB, CH1 and SH2 domains of Shc were expressed as glutathione-S-transferase (GST) fusion proteins and immobilized onto glutathione-Sepharose beads. Five g of GST or GST-fusion proteins were individually incubated with lysate (0.5 mg total protein) from 293T cells transfected with pcDNA3.1-mPAL. Coprecipitating proteins were resolved via SDS - PAGE, transferred to PVDF membrane, and immunoblotted with anti-mPAL antibody. The GST fusion proteins were visualized by Coomassie blue staining. (b) mPAL binds specifically to the SH2 domain of Shc. A panel of GST-SH2 fusion proteins (Shc SH2 domain, Grb2 SH2 domain, Vav SH2 domain, N-terminal SH2 domain of ras-GAP, N-terminal SH2 domain (p85-N) and C-terminal SH2 domain (p85-C) of p85 subunit of PI-3 kinase, N-terminal SH2 domain (PLC-N), and C-terminal SH2 domain (PLC-C) of phospholipase C-1, and Nck SH2 domain) were immobilized on glutathione-Sepharose beads. Five g of immobilized GST or GST-fusion protein were individually incubated with 293T-mPAL lysate, the beads washed several times, and the remaining bound proteins resolved via SDS - PAGE, transferred to PVDF membrane, and immunoblotted with anti-mPAL antibody
Figure 5 Binding of mPAL to Shc is phosphotyrosine-independent. (a) Association of GST-mPAL and Shc in NIH3T3 cells. Ten g of immobilized recombinant GST (GST), GST-Shc SH2 (GST-SH2) domain and GST-mPAL (GST-mPAL) fusion protein were individually incubated with approximately 1 mg of NIH3T3 lysate. The beads were washed several times, and the remaining bound proteins resolved via SDS - PAGE, transferred to PVDF membrane, and immunoblotted with either anti-Shc or anti-mPAL antibodies. (b) Free phosphotyrosine disrupts the mPAL-Shc SH2 interaction. 2.5 g of immobilized GST-Shc SH2 domain fusion protein was incubated with 293T-mPAL lysate in the presence of increasing concentrations of free phosphotyrosine, phosphoserine or phosphothreonine as indicated. The beads were washed several times, and the remaining bound proteins resolved via SDS - PAGE, transferred to PVDF membrane, and immunoblotted with anti-mPAL antibody. (c) Shc SH2 R397A does not interact with mPAL. A Shc SH2 domain mutant (SH2(R397A)) which is unable to bind to phosphotyrosine-containing substrates (R397 mutated to A), and the wild type Shc SH2 domain (SH2) were expressed as GST-fusion proteins, and immobilized onto glutathione-Sepharose beads. Five g of GST or GST-fusion protein were individually incubated with EGF stimulated HER14 cells (left panel) or 293T-mPAL lysate (right panel), the beads washed several times, the remaining bound proteins resolved via SDS - PAGE, transferred to PVDF membrane, and immunoblotted with anti-mPAL antibody. (d) Shc containing an inactivated SH2 domain does not coimmunoprecipitate with mPAL 293T cells were co-transfected with Flag-tagged wild type (wt) p52 Shc or R397A Shc (FLVAES) and pcDNA3.1-mPAL. Immunoprecipitations were peformed from cell lysates using a non-specific antibody (RM IgG) or with anti-FLAG and anti-mPAL antibodies. Immunoprecipitating proteins were resolved via SDS - PAGE. Following electrophoretic transfer to PVDF membrane, immunoblotting was performed with anti-Shc and anti-mPAL antibodies
Figure 6 Distribution of mPAL RNA in murine adult tissues. A multiple tissue Northern blot of poly (A)+ RNA extracted from adult murine tissues was purchased from Clontech. A 32P-labeled 1.5 kb AflIII/PstI fragment of mPAL cDNA was utilized as probe. Molecular weight standards are indicated. The membrane was exposed to X-ray film overnight at -80°C. Equal loading of mRNA was confirmed by reprobing the membrane with -actin
Figure 7 mPAL induction in serum-stimulated NIH3T3 cells. NIH3T3 cells were cultured in media containing 0.5% fetal calf serum for 48 h, then stimulated by addition of media containing 20% fetal calf serum. Following stimulation mRNA and protein was harvested from cells at the times indicated. (a) Northern blot analysis. Ten g of total RNA from each sample were separated on formaldehyde-agarose gels and transferred to Genescreen nylon membrane. Blots were probed for mPAL RNA as described above. This blot was exposed to X-ray film for 72 h at -80°C. The membrane was stripped and reprobed for Shc (lower panel). (b) Western blot analysis. At each timepoint, mPAL was immunoprecipitated from 1.0 mg of lysate and immunoblotted with anti-mPAL antibodies. In the lower panel, 20 g of whole cell lysate was immunoblotted for Shc. (c) Cell cycle analysis. Cells were harvested at each time point, stained with propidium iodide and subjected to cell cycle analysis by flow cytometry
Figure 8 mPAL expression is down-regulated following inhibition of cell growth. (a) mPAL levels are down-regulated upon contact inhibition. RNA was harvested from NIH3T3 cells over five consecutive days and the percentage confluence of each plate was noted at the time of harvest. mRNA samples (10 g/lane) were separated on formaldehyde-agarose gels and transferred onto Genescreen nylon membrane. Blots were probed for mPAL and exposed to X-ray film at -80°C for 2 days. Blots were stripped and reprobed for Shc expression. (b) Expression of mPAL decreases in differentiating P19 cells. The pluripotent murine embryonic carcinoma cell line, P19, was differentiated in the presence of retinoic acid and DMSO. mPAL immunoprecipitates from each sample were immunoblotted with anti-mPAL. This result was reproducibly obtained in three separate experiments. Twenty-five g of whole cell lysate was subjected to SDS - PAGE and Western blot analysis with anti- tubulin as probe to control for equal loading
Figure 9 mPAL expression is upregulated and associates with Shc following T-cell activation. (a) mPAL is expressed in anti-CD3 activated murine T-cells. T-cells isolated from wild type mice were stimulated by cross-linking the T-cell receptor with anti-CD3 antibodies. Samples were collected over 4 days and lysed in NP40 lysis buffer. mPAL was immunoprecipitated from 1.0 mg of lysate for each sample and Western blot analysis was performed with anti-mPAL antibodies. The blot was then stripped and immunoblotted with anti-Shc antibodies. (b) mPAL and Shc co-immunoprecipitate in activated T cells. T-cells isolated from wild type and CTLA4 deficient mice, as well as CD3 activated T cells, were lysed in NP40 lysis buffer. Shc and mPAL were each immunoprecipitated from 1 mg of lysate and immunoprecipitating proteins were resolved via SDS - PAGE. Duplicate gels were run and transferred to PVDF membrane. Membranes were immunoblotted for both Shc and mPAL. In order to clearly visualize Shc co-precipiation, the mPAL immunoprecipitations Western blotted with -Shc were overexposed relative to the corresponding Shc immunoprecipitations
|Received 3 August 1998; revised 22 October 1998; accepted 22 October 1998|
|11 March 1999, Volume 18, Number 10, Pages 1867-1879|
|Table of contents Previous Article Next [PDF]